Search Results - A. Avigdor

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    PB1809: CLINICAL TRAJECTORY OF LONG-TERM SURVIVORS OF ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE INDUCTION CHEMOTHERAPY by G. Heering, M. Sasson, D. Dominissini, A. Shimoni, A. Avigdor, A. Nagler, J. Canaani

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  2. 2

    P1571: EVALUATION OF THE CLINICAL IMPACT OF BONE MARROW CULTURES IN CURRENT MEDICAL PRACTICE by G. Sharvit, D. Schwartz, G. Heering, A. Shulman, A. Avigdor, G. Rahav, A. Toren, A. Nagler, J. Canaani

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA by S. Fried, M. J. Besser, E. Shkury, R. Yerushalmi, N. Shem-Tov, I. Danylesko, E. Jacoby, O. Itzhaki, R. Shouval, M. Kedmi, A. Shimoni, A. Nagler, A. Avigdor

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LAB... by A. F. Herrera, D. Lavie, N. A. Johnson, A. Avigdor, P. Borchmann, C. Andreadis, A. Bazargan, G. Gregory, C. Keane, T. Inna, V. Vucinic, P. L. Zinzani, H. Zhang, P. Pillai, P. Marinello, J. Timmerman

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  5. 5

    P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY... by G. Gregory, J. Timmerman, D. Lavie, P. Borchmann, A. F. Herrera, L. Minuk, V. Vucinic, P. Armand, A. Avigdor, R. Gasiorowski, Y. Herishanu, C. Keane, J. Kuruvilla, J. Palcza, P. Pillai, P. Marinello, N. A. Johnson

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: